Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer

Abstract

The continuous growth of tumors depends on the altered regulation of the cell cycle, which is in turn modulated by signals from growth factors and their receptors. Blockade of insulin-like growth factor (IGF)-I and IGF-IR by antisense or dominant negative plasmid transfection can suppress tumorigenicity and induce regression of established tumors. We have constructed two recombinant adenoviruses: an adenovirus expressing truncated IGF-IR (ad-IGF-IR/950) with an engineered stop codon at amino acid residue 950, and an adenovirus expressing the soluble extracellular domain of IGF-IR (ad-IGF-IR/482) with an engineered stop codon at amino acid residue 482. Ad-IGF-IR/950 produces a defective receptor with an intact α subunit and a defective β subunit lacking the tyrosine kinase domain. Dominant negative inhibition results from competition of the defective receptor with normal IGF-IR subunits, or the competition with normal IGF-IR for ligand by the soluble receptor. We were able to show here that ad-IGF-IR/950 induced the increased expression of IGF-IR on the cell surface and ad-IGF-IR/482 induced the secretion of the soluble fragment of IGF-IR. The transduction of both ad-IGF-IR/950 and ad-IGF-IR/482 could blunt the growth-stimulatory effect of IGF-I on human lung cancer cell lines. Both ad-IGF-IR/950 and ad-IGF-IR/482 effectively blocked IGF-I–induced Akt kinase activation. Intratumoral injection of ad-IGF-IR/482 virus showed significant growth suppression in established lung cancer xenografts. These findings suggest that these ad-IGF-IR/dn (950, 482) have the potential to be effective and practical cancer gene therapy strategies.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Baserga R . Oncogenes and the strategy of growth factor. Cell. 1994; 79: 927–930.

    Article  CAS  Google Scholar 

  2. Ullrich A, Gray A & Tam AW, et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 1986; 5: 2503–2512.

    Article  CAS  Google Scholar 

  3. Baserga R . The IGF-I receptor in cancer research. Exp Cell Res. 1999; 253: 1–6.

    Article  CAS  Google Scholar 

  4. Baserga R . The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta. 1997; 1332: F105–F126.

    CAS  PubMed  Google Scholar 

  5. Resnikoff M, Sell C & Rubini M, et al. Rat glioblastoma cells expressing an antisense RNA to insulin-like growth factor I (IGF-I) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res. 1994; 54: 2218–2222.

    Google Scholar 

  6. Resnicoff M, Coppola D, Sell C, Rubin R, Ferrone S & Baserga R . Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res. 1994; 54: 4848–4850.

    CAS  PubMed  Google Scholar 

  7. Prager D, Li HL, Asa S & Melmed S . Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc Natl Acad Sci USA. 1994; 91: 2181–2185.

    Article  CAS  Google Scholar 

  8. Miura M, Li S & Baserga R . Effect of a mutation at tyrosine 950 of the insulin-like growth factor I receptor on the growth and transformation of cells. Cancer Res. 1995; 55: 663–667.

    CAS  PubMed  Google Scholar 

  9. Burgaud JL, Resnikoff M & Baserga R . Mutant IGF-I receptors as dominant negatives for growth and transformation. Biochem Biophys Res Commun. 1995; 214: 475–481.

    Article  CAS  Google Scholar 

  10. Reiss K, D'Ambrosio C, Tu X, Tu C & Baserga R . Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect. Clin Cancer Res. 1998; 4: 2647–2655.

    CAS  PubMed  Google Scholar 

  11. Dunn SE, Ehrlich M & Sharp NJ, et al. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res. 1998; 58: 3353–3361.

    CAS  PubMed  Google Scholar 

  12. Rininsland F, Johnson TR & Chernicky CL, et al. Suppression of insulin-like growth factor type I receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells. Proc Natl Acad Sci USA. 1997; 94: 5854–5859.

    Article  CAS  Google Scholar 

  13. Graham FL & Prevec L . Manipulation of adenovirus vectors. In: Murray E, edGene Transfer and Expression Protocols, Clifton, NJ: Humana Press; 1991; 109–128.

    Chapter  Google Scholar 

  14. Tang DC, Johnston SA & Carbone DP . Tumor-restricted gene expression by adenovirus-mediated gene transfer. Cancer Gene Ther. 1994; 1: 15–20.

    CAS  PubMed  Google Scholar 

  15. Lee C-T, Wu S & Gabrilovich D, et al. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines. Cancer Res. 1996; 56: 3038–3041.

    CAS  PubMed  Google Scholar 

  16. Becker TC, Noel RJ & Coats WS, et al. Use of recombination of adenovirus for metabolic engineering of mammalian cells. In: Roth MG, edProtein Expression in Animal Cells, New York: Academic Press; 1994; 161–188.

    Chapter  Google Scholar 

  17. Kim SO, Park JG & Lee YI . Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: implications of IGF-I receptor gene activation by hepatitis B virus X gene products. Cancer Res. 1996; 56: 3831–3836.

    CAS  PubMed  Google Scholar 

  18. Kulik G, Klippel A & Weber MJ . Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol. 1998; 18: 1595–1606.

    Article  Google Scholar 

  19. Kulik G & Weber MJ . Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor-I. Mol Cell Biol. 1998; 18: 6711–6718.

    Article  CAS  Google Scholar 

  20. Grimberg A & Cohen P . Growth hormone and prostate cancer: guilty by association?. J Endocrinol Invest. 1999; 22: 64–73.

    Article  CAS  Google Scholar 

  21. Ma J, Pollack MN & Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 1999; 91: 620–625.

    Article  CAS  Google Scholar 

  22. Yu H, Spitz MR, Mistry J, Gu J, Hong WK & Wu X . Plasma levels of insulin-like growth factor-I and lung cancer risk: a case control analysis. J Natl Cancer Inst. 1999; 91: 151–156.

    Article  CAS  Google Scholar 

  23. Scotland K, Benini S & Nani P, et al. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic nude mice. Cancer Res. 1999; 58: 4127–4131.

    Google Scholar 

  24. Trojan J, Blossey BK & Johnson TR, et al. Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. Proc Natl Acad Sci USA. 1992; 89: 4874–4878.

    Article  CAS  Google Scholar 

  25. Hongo A, Yumet G, Resnicoff M, Romano G, O'Connor R & Baserga R . Inhibition of tumorigenesis and induction of apoptosis in human tumor cells by the stable expression of a myristoylated COOH terminus of insulin-like growth factor I receptor. Cancer Res. 1998; 58: 2477–2484.

    CAS  PubMed  Google Scholar 

  26. Datta SR, Dudek H & Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997; 91: 231–241.

    Article  CAS  Google Scholar 

  27. del Peso L, Gonzalez-Garcia M, Page C, Herrera R & Nunez G . Interleukin-3–induced phosphorylation of BAD through the protein kinase Akt. Science. 1997; 278: 687–689.

    Article  CAS  Google Scholar 

  28. Parrizas M, Saltiel AR & LeRoith D . Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways. J Biol Chem. 1997; 272: 154–161.

    Article  CAS  Google Scholar 

  29. Peruzzi F, Prisco M & Dews M, et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol. 1999; 19: 7203–7215.

    Article  CAS  Google Scholar 

  30. D'Ambrosio C, Ferber A, Resnicoff M & Baserga R . A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res. 1996; 56: 4013–4020.

    CAS  PubMed  Google Scholar 

  31. Jiang Y, Rom WN, Yie T-A, Chi CX & Tchou-Wong K-M . Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor. Oncogene. 1999; 18: 6071–6077.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work is supported by Grants from the Medical Research Center from Seoul National University (2000) to C-T Lee and DP Carbone (NCI 5P30CA68485).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to David P Carbone.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, CT., Park, KH., Adachi, Y. et al. Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer. Cancer Gene Ther 10, 57–63 (2003). https://doi.org/10.1038/sj.cgt.7700524

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700524

Keywords

This article is cited by

Search

Quick links